Ideaya plans to submit an investigational new drug application next year for IDE034, a B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate.
The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback